HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives

HER-2 (ErbB-2, c-erbB2 or Her2/neu), a member of the HER-family, is directly involved in the pathogenesis and progression of several human cancers; as such, it is also often considered as a poor prognostic factor. Following the revolutionary impact of anti-HER-2 therapy in breast cancer patients, th...

Descripción completa

Detalles Bibliográficos
Autores principales: Fanotto, Valentina, Ongaro, Elena, Rihawi, Karim, Avallone, Antonio, Silvestris, Nicola, Fornaro, Lorenzo, Vasile, Enrico, Antonuzzo, Lorenzo, Leone, Francesco, Rosati, Gerardo, Giuliani, Francesco, Bordonaro, Roberto, Scartozzi, Mario, Maglio, Giovanna De, Negri, Francesca V., Fasola, Gianpiero, Aprile, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356612/
https://www.ncbi.nlm.nih.gov/pubmed/27542243
http://dx.doi.org/10.18632/oncotarget.11264
_version_ 1782515873569832960
author Fanotto, Valentina
Ongaro, Elena
Rihawi, Karim
Avallone, Antonio
Silvestris, Nicola
Fornaro, Lorenzo
Vasile, Enrico
Antonuzzo, Lorenzo
Leone, Francesco
Rosati, Gerardo
Giuliani, Francesco
Bordonaro, Roberto
Scartozzi, Mario
Maglio, Giovanna De
Negri, Francesca V.
Fasola, Gianpiero
Aprile, Giuseppe
author_facet Fanotto, Valentina
Ongaro, Elena
Rihawi, Karim
Avallone, Antonio
Silvestris, Nicola
Fornaro, Lorenzo
Vasile, Enrico
Antonuzzo, Lorenzo
Leone, Francesco
Rosati, Gerardo
Giuliani, Francesco
Bordonaro, Roberto
Scartozzi, Mario
Maglio, Giovanna De
Negri, Francesca V.
Fasola, Gianpiero
Aprile, Giuseppe
author_sort Fanotto, Valentina
collection PubMed
description HER-2 (ErbB-2, c-erbB2 or Her2/neu), a member of the HER-family, is directly involved in the pathogenesis and progression of several human cancers; as such, it is also often considered as a poor prognostic factor. Following the revolutionary impact of anti-HER-2 therapy in breast cancer patients, the role of HER-2 and its blockade has also been extensively evaluated in other tumor types, including gastric and colorectal adenocarcinoma. The aims of this review are to recall the important results achieved with the use of HER-2 inhibitors in both gastric and colorectal cancer, and to discuss on the updates available on the role of HER-2 as prognostic and predictive factor in these malignancies.
format Online
Article
Text
id pubmed-5356612
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-53566122017-03-24 HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives Fanotto, Valentina Ongaro, Elena Rihawi, Karim Avallone, Antonio Silvestris, Nicola Fornaro, Lorenzo Vasile, Enrico Antonuzzo, Lorenzo Leone, Francesco Rosati, Gerardo Giuliani, Francesco Bordonaro, Roberto Scartozzi, Mario Maglio, Giovanna De Negri, Francesca V. Fasola, Gianpiero Aprile, Giuseppe Oncotarget Review HER-2 (ErbB-2, c-erbB2 or Her2/neu), a member of the HER-family, is directly involved in the pathogenesis and progression of several human cancers; as such, it is also often considered as a poor prognostic factor. Following the revolutionary impact of anti-HER-2 therapy in breast cancer patients, the role of HER-2 and its blockade has also been extensively evaluated in other tumor types, including gastric and colorectal adenocarcinoma. The aims of this review are to recall the important results achieved with the use of HER-2 inhibitors in both gastric and colorectal cancer, and to discuss on the updates available on the role of HER-2 as prognostic and predictive factor in these malignancies. Impact Journals LLC 2016-08-12 /pmc/articles/PMC5356612/ /pubmed/27542243 http://dx.doi.org/10.18632/oncotarget.11264 Text en Copyright: © 2016 Fanotto et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Review
Fanotto, Valentina
Ongaro, Elena
Rihawi, Karim
Avallone, Antonio
Silvestris, Nicola
Fornaro, Lorenzo
Vasile, Enrico
Antonuzzo, Lorenzo
Leone, Francesco
Rosati, Gerardo
Giuliani, Francesco
Bordonaro, Roberto
Scartozzi, Mario
Maglio, Giovanna De
Negri, Francesca V.
Fasola, Gianpiero
Aprile, Giuseppe
HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives
title HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives
title_full HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives
title_fullStr HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives
title_full_unstemmed HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives
title_short HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives
title_sort her-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356612/
https://www.ncbi.nlm.nih.gov/pubmed/27542243
http://dx.doi.org/10.18632/oncotarget.11264
work_keys_str_mv AT fanottovalentina her2inhibitioningastricandcolorectalcancerstangibleachievementsnovelacquisitionsandfutureperspectives
AT ongaroelena her2inhibitioningastricandcolorectalcancerstangibleachievementsnovelacquisitionsandfutureperspectives
AT rihawikarim her2inhibitioningastricandcolorectalcancerstangibleachievementsnovelacquisitionsandfutureperspectives
AT avalloneantonio her2inhibitioningastricandcolorectalcancerstangibleachievementsnovelacquisitionsandfutureperspectives
AT silvestrisnicola her2inhibitioningastricandcolorectalcancerstangibleachievementsnovelacquisitionsandfutureperspectives
AT fornarolorenzo her2inhibitioningastricandcolorectalcancerstangibleachievementsnovelacquisitionsandfutureperspectives
AT vasileenrico her2inhibitioningastricandcolorectalcancerstangibleachievementsnovelacquisitionsandfutureperspectives
AT antonuzzolorenzo her2inhibitioningastricandcolorectalcancerstangibleachievementsnovelacquisitionsandfutureperspectives
AT leonefrancesco her2inhibitioningastricandcolorectalcancerstangibleachievementsnovelacquisitionsandfutureperspectives
AT rosatigerardo her2inhibitioningastricandcolorectalcancerstangibleachievementsnovelacquisitionsandfutureperspectives
AT giulianifrancesco her2inhibitioningastricandcolorectalcancerstangibleachievementsnovelacquisitionsandfutureperspectives
AT bordonaroroberto her2inhibitioningastricandcolorectalcancerstangibleachievementsnovelacquisitionsandfutureperspectives
AT scartozzimario her2inhibitioningastricandcolorectalcancerstangibleachievementsnovelacquisitionsandfutureperspectives
AT magliogiovannade her2inhibitioningastricandcolorectalcancerstangibleachievementsnovelacquisitionsandfutureperspectives
AT negrifrancescav her2inhibitioningastricandcolorectalcancerstangibleachievementsnovelacquisitionsandfutureperspectives
AT fasolagianpiero her2inhibitioningastricandcolorectalcancerstangibleachievementsnovelacquisitionsandfutureperspectives
AT aprilegiuseppe her2inhibitioningastricandcolorectalcancerstangibleachievementsnovelacquisitionsandfutureperspectives

Ejemplares similares